drugset / Trial / NCT00008697
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Phase 1/2
Completed
13 enrolled
Washington University School of Medicine
National Cancer Institute (NCI) · collab
RandomizedParallel-groupTreatment
Summary
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic response and therapy-related toxicities will be sought.
Timeline
- Start
- 1998-11
- Primary completion
- 2002-04
- Completion
- 2002-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.1 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.25 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.3 mg/kg | Intravenous |